Form 4: ResMed CFO Brett Sandercock Sells 1,000 Shares Under 10b5-1 Plan

ResMed's Chief Financial Officer, Brett Sandercock, executed a sale of 1,000 shares of ResMed Common Stock at a price of $194.35 per share on July 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 8, 2024, Brett Sandercock, the Chief Financial Officer of ResMed Inc., sold 1,000 shares of ResMed Common Stock.
• The sale was executed at a price of $194.35 per share.
• The transaction was conducted under a Rule 10b5-1 plan adopted on February 6, 2024.
• Following the transaction, Sandercock directly owns 90,056 shares of ResMed Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale. It doesn't inherently convey positive or negative sentiment, as it's a routine transaction under a pre-arranged plan.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on non-public information. The market typically views these sales in the context of the overall insider ownership and the reasons behind the sale (e.g., diversification, personal financial planning).

Stakeholder Impact

• The sale of shares by the CFO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the relatively small number of shares sold and the existence of a pre-arranged trading plan.

Key Dates